Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VTX3940
- Development stage
- Unknown
- Lead developer
- Ventyx Biosciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
VTX3940 is a code-named compound that was part of Ventyx Biosciences' pipeline of oral small molecule therapeutics. Ventyx Biosciences, a clinical-stage biopharmaceutical company, was acquired by Eli Lilly and Company. While Ventyx's pipeline generally focuses on inflammatory-mediated diseases, including NLRP3, TYK2, and S1P1R inhibitors, specific details regarding the mechanism of action, primary indication, and development status for VTX3940 are not publicly available from the provided context or general search results.
Beyond the preview
Go deeper on VTX3940.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VTX3940.